GSK stock heads into the open after a 1.2% decline

At the close on September 21, 2026, GSK stock finished at GBX 1,877.50 on the London Stock Exchange, down 1.2%. The shares traded between GBX 1,852.50 and GBX 1,912.00 as the FTSE 100 slipped 0.2%.

GSK stock closed at GBX 1,877.50 on the London Stock Exchange on September 21, 2026, down 1.18% from the previous session. The shares moved between an intraday low of GBX 1,852.50 and a high of GBX 1,912.00, with volume of about 15.67 million shares, while the London Stock Exchange benchmark index closed at 8,246.0, down 0.19%.

September 21, 2026 in numbers

GSK plc (ISIN GB0009252882) saw its share price slip to GBX 1,877.50 at the London Stock Exchange close on September 21, 2026, a decline of 22.50 points or 1.18% on the day. According to the live quote overview at Investing.com, the session range spanned from GBX 1,852.50 at the low to GBX 1,912.00 at the high, with reported turnover of roughly 15.67 million shares and the London Stock Exchange index ending at 8,246.0, down 16.0 points or 0.19% on the same date.Investing.com The single session profile therefore shows GSK underperforming the broader London equity market on September 21, 2026, with the stock losing 1.18% against a 0.19% decline for the home index.

Today’s focus for GSK stock

Looking ahead to today, September 22, 2026, investors continue to monitor GSK against developments in its pharmaceuticals and consumer health markets, with attention also on broader equity sentiment after the modest pullback in London benchmarks in the last session. Recent communications from GSK’s HIV joint venture ViiV Healthcare highlighted new investment commitments in paediatric and adolescent treatment access, underscoring the group’s ongoing strategic focus on its specialty medicines franchise.ViiV Healthcare While this announcement did not have a clearly quantified impact on the September 21, 2026 session, it remains part of the backdrop as GSK stock heads into today’s open.